Effect of cranberry supplement on long-term consequences of metabolic syndrome

The effect of cranberry supplementation on glucose, lipid, oxidative stress, inflammation markers, fat mass distribution and blood pressure in overweight women with metabolic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110192480N2

Enrollment

Registered

2012-01-21

Start date

2011-11-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome. Personal history of endocrine, nutritional and metabolic diseases

Interventions

Intervention 1: Cranberry supplements intake is equivalent to 400 mg fruit extract per day, for 2 months. Intervention 2: placebo intake for 2 months.

Treatment - Drugs

Placebo

Cranberry supplements intake is equivalent to 400 mg fruit extract per day, for 2 months

placebo intake for 2 months

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women with features of metabolic syndrome between 20 and 50 years of age, BMI>25. Exclusion criteria: Postmenopausal women; medications for any chronic disease (cancer, diabetes, CVD); use of medication known to affect lipid metabolism or possess anti-inflammatory effect; Smoking; Alcohol consumption; use of supplements (antioxidants, multivitamins,...); Chronic disease: renal, liver, thyroid, etc; pregnant or lactating; use of warfarin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipid profile. Timepoint: Before and 2 months after intervention. Method of measurement: Auto analyzer.;FBS. Timepoint: Before and 2 months after intervention. Method of measurement: Auto analyzer.;Systolic and diastolic blood pressure. Timepoint: Before and 2 months after intervention. Method of measurement: Mercury Barometer.;Waist circumference. Timepoint: Before and 2 months after intervention. Method of measurement: Tape Meter.	—

Measure

Time frame

Lipid profile. Timepoint: Before and 2 months after intervention. Method of measurement: Auto analyzer.;FBS. Timepoint: Before and 2 months after intervention. Method of measurement: Auto analyzer.;Systolic and diastolic blood pressure. Timepoint: Before and 2 months after intervention. Method of measurement: Mercury Barometer.;Waist circumference. Timepoint: Before and 2 months after intervention. Method of measurement: Tape Meter.

—

Secondary

Measure	Time frame
Insulin. Timepoint: Before and 2 months after intervention. Method of measurement: ELISA kit.;Interlukin-6 (IL-6). Timepoint: Before and 2 months after intervention. Method of measurement: RIA.;HsCRP. Timepoint: Before and 2 months after intervention. Method of measurement: ELISA kit.;Adiponectin. Timepoint: Before and 2 months after intervention. Method of measurement: ELISA kit.;Malon-dialdehide(MDA). Timepoint: Before and 2 months after intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Insulin. Timepoint: Before and 2 months after intervention. Method of measurement: ELISA kit.;Interlukin-6 (IL-6). Timepoint: Before and 2 months after intervention. Method of measurement: RIA.;HsCRP. Timepoint: Before and 2 months after intervention. Method of measurement: ELISA kit.;Adiponectin. Timepoint: Before and 2 months after intervention. Method of measurement: ELISA kit.;Malon-dialdehide(MDA). Timepoint: Before and 2 months after intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansooreh Alaei

School of health & nutrition, Shiraz University of Medical Sciences

maalaei@yahoo.com , schealth@sums.ac.ir+98 71172510018

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026